Filing Analysis
Foghorn Therapeutics Inc. held its 2026 Annual Meeting of Stockholders on June 24, 2026. The meeting resulted in the election of three Class III directors and the ratification of Deloitte & Touche LLP as the independent auditor.
📋 Key Facts
- Annual Meeting held on June 24, 2026.
- Elected Douglas Cole, M.D., Balkrishan (Simba) Gill, Ph.D., and B. Lynne Parshall to the Board of Directors for three-year terms.
- Ratified Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending Dec 31, 2026.
- Stockholders approved advisory votes on executive compensation and the frequency of future advisory votes (one-year cycle).
- Total shares entitled to vote: 58,713,922; Shares present/represented: 51,708,896.
Foghorn Therapeutics Inc. announced the resignation of Adam M. Koppel, M.D., Ph.D. from its Board of Directors, effective December 29, 2024. The filing explicitly states that his departure was not due to any disagreement with the Company or its Board regarding operations, policies, or practices.
🚩 Red Flags
- None identified; departure is characterized as non-dispute related.
📋 Key Facts
- Adam M. Koppel resigned as a director effective December 29, 2024.
- Dr. Koppel served on the Audit Committee and the Nominating and Corporate Governance Committee.
- He was a Class II director with a term expiring at the 2025 Annual Meeting.
- The resignation was not due to any disagreement with the Company or its Board.
Foghorn Therapeutics is discontinuing the independent development of its FHD-286 drug candidate in combination with decitabine for treating relapsed or refractory acute myeloid leukemia. The company also provided an updated investor presentation via Regulation FD disclosure.
🚩 Red Flags
- Pipeline setback: Discontinuation of a clinical development program (FHD-286) reduces the company's therapeutic options and potential value drivers.
📋 Key Facts
- Discontinuation of independent development of FHD-286 + decitabine for relapsed/refractory AML.
- Filed under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Information).
- Investor presentation dated December 2024 provided as Exhibit 99.1.
Foghorn Therapeutics Inc. filed an 8-K to announce its quarterly financial results for the period ended September 30, 2024 and provided an updated investor presentation.
📋 Key Facts
- Company released Q3 2024 financial results on November 4, 2024.
- An investor presentation dated November 2024 was furnished as Exhibit 99.2.
- The filing includes a press release regarding financial condition (Exhibit 99.1).
Foghorn Therapeutics announced a clinical milestone regarding its Phase 1 trial for FHD-909. The company also furnished an investor presentation under Regulation FD.
📋 Key Facts
- First patient has been dosed with FHD-909 (LY4050784) in a Phase 1 clinical trial.
- The trial targets cancers with SMARCA4 (BRG1) mutations, specifically focusing on non-small cell lung cancer (NSCLC).
- Company furnished an investor presentation dated October 2024 as Exhibit 99.1.
Foghorn Therapeutics Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024 and provided an updated investor presentation.
📋 Key Facts
- Announced financial results for the second quarter ended June 30, 2024 (Item 2.02).
- Furnished an investor presentation dated August 2024 (Item 7.01).
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Investor Presentation).
Foghorn Therapeutics Inc. held its 2024 Annual Meeting of Stockholders on June 26, 2024. All proposals, including the election of Class I directors and the ratification of Deloitte & Touche LLP as independent auditors, were approved by stockholders.
📋 Key Facts
- Annual Meeting held on June 26, 2024.
- Total shares entitled to vote: 42,585,616; Shares present/represented: 30,381,145.
- Scott Biller, Ph.D., Thomas J. Lynch, M.D., and Michael Mendelsohn, M.D., were elected as Class I directors for three-year terms.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
Foghorn Therapeutics Inc. filed an 8-K to furnish an investor presentation dated June 2024 under Item 7.01 (Regulation FD Disclosure). The filing is intended for use in meetings or presentations with investors and does not contain material non-public information that would trigger a high-severity event.
📋 Key Facts
- Company furnished an investor presentation dated June 2024 as Exhibit 99.1.
- The disclosure is made pursuant to Item 7.01 (Regulation FD Disclosure).
- Information provided under Item 7.01 is being furnished but not 'filed' for purposes of Section 18 of the Exchange Act.
Foghorn Therapeutics Inc. filed an 8-K to furnish an investor presentation dated May 23, 2024, pursuant to Regulation FD.
📋 Key Facts
- The filing is a routine disclosure of an investor presentation under Item 7.01 (Regulation FD Disclosure).
- The presentation was filed on May 23, 2024.
- The information provided in the exhibit is intended for use in meetings or presentations to investors and is not considered 'filed' for liability purposes under Section 18 of the Exchange Act.
Foghorn Therapeutics Inc. entered into an underwriting agreement on May 20, 2024, for a public offering of common stock and pre-funded warrants. The offering aims to raise capital through the sale of approximately 12.7 million shares and 7.2 million pre-funded warrants.
🚩 Red Flags
- Significant dilution: The offering of ~12.7M shares and ~7.2M warrants represents a substantial increase in share count.
- Use of pre-funded warrants often indicates difficulty in attracting standard equity investors, requiring warrants to bypass certain ownership thresholds.
📋 Key Facts
- Underwriting agreement dated May 20, 2024, with Jefferies LLC, TD Securities (USA) LLC, and Evercore Group L.L.C. as representatives.
- Public offering of 12,743,039 shares of common stock at $5.51 per share.
- Issuance of 7,220,794 pre-funded warrants at a price of $5.5099 per warrant.
- Pre-funded warrants are exercisable at any time and do not expire.
- Warrants include a 9.99% ownership cap upon exercise to prevent immediate change in control, with provisions for up to 19.99% upon notice.
Foghorn Therapeutics Inc. filed an 8-K to furnish an investor presentation dated May 20, 2024. This is a routine regulatory filing used to provide supplemental information to the market.
📋 Key Facts
- The company furnished Exhibit 99.1, which is an Investor Presentation dated May 20, 2024.
- The presentation is intended for use in meetings with or presentations to investors.
- The disclosure is made under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
Foghorn Therapeutics Inc. filed an 8-K to announce the publication of an investor presentation on its website as of May 6, 2024.
📋 Key Facts
- The company posted an investor presentation to its website on May 6, 2024.
- The presentation is intended for use in meetings with investors.
- Exhibit 99.1 contains the full text of the presentation.
Foghorn Therapeutics Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2024. The filing serves as a formal announcement of the company's recent earnings performance.
📋 Key Facts
- Report date: May 6, 2024
- Reporting period: Quarter ended March 31, 2024
- The filing includes Exhibit 99.1 containing the press release of financial results.
- Company is an emerging growth company.
Foghorn Therapeutics Inc. announced the appointment of Kristian F. Humer as Chief Financial Officer, effective April 16, 2024. This transition marks the conclusion of Stephen DiPalma's tenure as Interim CFO.
📋 Key Facts
- Kristian F. Humer appointed as CFO, Principal Financial Officer, and Principal Accounting Officer on April 16, 2024.
- Humer previously served as Chief Financial and Chief Business Officer at Viridian Therapeutics.
- Compensation includes a $475,000 annual base salary and an $87,000 signing bonus.
- Equity component: 275,000 stock options under the 2020 Equity Incentive Plan with a 3-year vesting schedule.
- Stephen DiPalma ceases to serve as Interim CFO.
Foghorn Therapeutics Inc. issued an 8-K to provide pipeline updates and preclinical data presented at the 2024 AACR Annual Meeting. The filing includes investor presentations and a press release regarding multiple research programs.
📋 Key Facts
- Company hosted a conference call/webcast on April 9, 2024, to review pipeline updates from the AACR Annual Meeting.
- Announced preclinical data for BRM selective inhibitor FHD-909, selective CBP degrader, and selective EP300 degrader programs.
- Furnished an investor presentation dated April 2024 (Exhibit 99.2).
- Issued a press release regarding poster presentations at AACR 2024 (Exhibit 99.3).
Foghorn Therapeutics Inc. filed an 8-K to announce its full-year financial results for the period ending December 31, 2023, and provided an updated investor presentation.
📋 Key Facts
- Announced year-end financial results for the fiscal year ended December 31, 2023.
- Issued a press release (Exhibit 99.1) containing detailed financial performance data.
- Provided an investor presentation (Exhibit 99.2) intended for use in meetings with or presentations to investors.
Foghorn Therapeutics announced that Eli Lilly and Company has selected the company's FHD-909 candidate for clinical development. This partnership involves Lilly planning to file an IND for the drug in Q2 2024.
📋 Key Facts
- Eli Lilly and Company (Lilly) has selected FHD-909 for clinical development.
- FHD-909 is a first-in-class oral BRM selective inhibitor of BRG1.
- Target indication: BRG1 mutated non-small cell lung cancer.
- Lilly plans to file an Investigational New Drug (IND) application in the second quarter of 2024.
Foghorn Therapeutics Inc. has appointed Stephen J. DiPalma as interim Chief Financial Officer (CFO) and Treasurer, effective January 16, 2024. The company is currently conducting a search for a permanent CFO replacement.
🚩 Red Flags
- Interim appointment suggests a sudden or unplanned departure of the previous CFO (though specific cause is not stated).
- Use of an external consultancy (Danforth Advisors) for interim executive functions can sometimes indicate a transition period during which internal controls are being reviewed.
📋 Key Facts
- Stephen J. DiPalma appointed as Treasurer and interim CFO effective Jan 16, 2024.
- The appointment is through Danforth Advisors, LLC, a strategic and financial consulting firm already providing services to the company.
- Mr. DiPalma will be compensated via an hourly rate paid to Danforth Advisors, LLC plus expense reimbursement.
- The company has not yet filled the permanent CFO position.
Foghorn Therapeutics Inc. filed an 8-K to furnish a press release and an investor presentation dated January 2024 under Regulation FD.
📋 Key Facts
- The filing was made on January 8, 2024.
- Exhibit 99.1 is a press release issued on the same date.
- Exhibit 99.2 is an investor presentation dated January 2024 intended for use in meetings with investors.
Foghorn Therapeutics Inc. announced the resignation of its Chief Financial Officer, Allan Reine, M.D., effective January 16, 2024. The departure is stated to be for personal reasons and not related to any disagreements regarding company operations or financial controls.
🚩 Red Flags
- Sudden departure of a key C-suite executive (CFO) in a micro-cap/biotech environment can sometimes precede volatility, though the filing explicitly denies disagreement.
📋 Key Facts
- Allan Reine, M.D. resigned as CFO on December 29, 2023.
- Effective date of resignation: January 16, 2024.
- The departure is not due to any disagreement with the Company regarding operations, policies, practices, financial controls, or audit procedures.
- The Company has initiated a search for a replacement CFO.